Dataset Information

Willingness to pay for SARS-CoV-2 rapid antigen tests during the COVID-19 pandemic: evidence from the general adult population.

ABSTRACT:

Objective

Our aim was to examine the willingness to pay (WTP) for SARS-CoV-2 rapid antigen tests and its correlates during the COVID-19 pandemic in Germany.

Study design/methods

A representative online survey was conducted in late summer 2021 (with n = 3075; the average age was 44.5 years; 14.8 years ranging from 18 to 70 years) in Germany. Two-part models were conducted. Various correlates (such as empathy or altruism) were included in the regression analysis.

Results

The average WTP for SARS-CoV-2 rapid antigen tests (in euros) was 6.6 (standard deviation 8.4) in the general adult population. It markedly differed between subgroups (e.g. the average WTP was 2.9 among individuals not vaccinated against COVID-19 and 7.5 among individuals vaccinated against COVID-19; it was 5.4 among the lowest income decile, whereas it was 8.6 among the highest income decile). Regressions showed that a higher WTP for SARS-CoV-2 rapid antigen tests was associated with being male, being in the highest income group, being vaccinated against COVID-19, and having higher levels of empathy.

Conclusions

As the very first study in this area, our study described WTP for SARS-CoV-2 rapid antigen tests and some interesting differences between population subgroups. In particular, individuals not vaccinated against COVID-19 reported a low WTP for SARS-CoV-2 rapid antigen tests. Approximately one-fourth of the sample reported a WTP for SARS-CoV-2 rapid antigen tests of €0 among individuals vaccinated against COVID-19, whereas approximately two-thirds of those not vaccinated against COVID-19 reported such a WTP. Knowledge about the WTP for COVID-19 rapid antigen tests is important for policy makers (e.g. for testing strategies) during this pandemic. It may also give a rough estimation of the acceptance of such rapid tests.

SUBMITTER: Hajek A

PROVIDER: S-EPMC8968124 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Willingness to pay for SARS-CoV-2 rapid antigen tests during the COVID-19 pandemic: evidence from the general adult population.

Hajek André A König Hans-Helmut HH

Public health 20220331

<h4>Objective</h4>Our aim was to examine the willingness to pay (WTP) for SARS-CoV-2 rapid antigen tests and its correlates during the COVID-19 pandemic in Germany.<h4>Study design/methods</h4>A representative online survey was conducted in late summer 2021 (with n = 3075; the average age was 44.5 years; 14.8 years ranging from 18 to 70 years) in Germany. Two-part models were conducted. Various correlates (such as empathy or altruism) were included in the regression analysis.<h4>Results</h4>The ...[more]

PMID: 35483163

Similar Datasets

Project description:BackgroundRapid antigen diagnostic tests (Ag-RDTs) are the most widely used point-of-care tests for detecting SARS-CoV-2 infection. Since the accuracy may have altered by changes in SARS-CoV-2 epidemiology, indications for testing, sampling and testing procedures, and roll-out of COVID-19 vaccination, we evaluated the performance of three prevailing SARS-CoV-2 Ag-RDTs.MethodsIn this cross-sectional study, we consecutively enrolled individuals aged >16 years presenting for SARS-CoV-2 testing at three Dutch public health service COVID-19 test sites. In the first phase, participants underwent either BD-Veritor System (Becton Dickinson), PanBio (Abbott), or SD-Biosensor (Roche Diagnostics) testing with routine sampling procedures. In a subsequent phase, participants underwent SD-Biosensor testing with a less invasive sampling method (combined oropharyngeal-nasal [OP-N] swab). Diagnostic accuracies were assessed against molecular testing.ResultsSix thousand nine hundred fifty-five of 7005 participants (99%) with results from both an Ag-RDT and a molecular reference test were analysed. SARS-CoV-2 prevalence and overall sensitivities were 13% (188/1441) and 69% (129/188, 95% CI 62-75) for BD-Veritor, 8% (173/2056) and 69% (119/173, 61-76) for PanBio, and 12% (215/1769) and 74% (160/215, 68-80) for SD-Biosensor with routine sampling and 10% (164/1689) and 75% (123/164, 68-81) for SD-Biosensor with OP-N sampling. In those symptomatic or asymptomatic at sampling, sensitivities were 72-83% and 54-56%, respectively. Above a viral load cut-off (≥5.2 log10 SARS-CoV-2 E-gene copies/mL), sensitivities were 86% (125/146, 79-91) for BD-Veritor, 89% (108/121, 82-94) for PanBio, and 88% (160/182, 82-92) for SD-Biosensor with routine sampling and 84% (118/141, 77-89) with OP-N sampling. Specificities were >99% for all tests in most analyses. Sixty-one per cent of false-negative Ag-RDT participants returned for testing within 14 days (median: 3 days, interquartile range 3) of whom 90% tested positive.ConclusionsOverall sensitivities of three SARS-CoV-2 Ag-RDTs were 69-75%, increasing to ≥86% above a viral load cut-off. The decreased sensitivity among asymptomatic participants and high positivity rate during follow-up in false-negative Ag-RDT participants emphasise the need for education of the public about the importance of re-testing after an initial negative Ag-RDT should symptoms develop. For SD-Biosensor, the diagnostic accuracy with OP-N and deep nasopharyngeal sampling was similar; adopting the more convenient sampling method might reduce the threshold for professional testing.

Dataset Information

Willingness to pay for SARS-CoV-2 rapid antigen tests during the COVID-19 pandemic: evidence from the general adult population.

Objective

Study design/methods

Results

Conclusions

Publications

Willingness to pay for SARS-CoV-2 rapid antigen tests during the COVID-19 pandemic: evidence from the general adult population.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets